USPTO serial 79350511
INDIMIX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 14, 2025
- Examiner
- MESSICK, TABITHA LEE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INDIMIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leo M. Loughlin
Leo M. Loughlin Rothwell, Figg, Ernst & Manbeck, PC901 New York Avenue, N.W.Suite 900 EastWashington, DC 20001Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical and biotechnological reagents for industrial and scientific purposes and laboratory analysis, other than in vivo use and other than for medical or veterinary purposes; Chemical, biochemical and biotechnological substances for industrial and scientific purposes and laboratory analysis, other than in vivo use and other than for medical or veterinary purposes; Biochemicals for scientific and research use, namely, for sample preparation, modification and manipulation of cells and for labeling, isolation, purification, amplification and analysis of natural and synthetic biopolymers in the nature of nucleotides, buffer substances such as salts and proteins for industrial use, macromolecules and biologically active substances, none of the foregoing for medical or veterinary use; biochemicals, namely, small molecular chemicals for scientific or research use; laboratory chemicals, namely, small molecular chemicals used for the detection of nucleic acids in cell and tissue analysis for in vitro diagnostic use; chemicals and biochemical preparations used in industry, in particular, chemical and biochemical substances for molecular biological, biochemical and immunological laboratory testing and analysis, other than for medical or veterinary purposes; kits comprising biochemical reagents for scientific and research use, namely, for sample preparation, modification and manipulation of samples and cells and for labeling, separation, isolation, purification, especially amplification and analysis of natural and synthetic biopolymers, in particular, nucleic acids for laboratory use, oligonucleotides, proteins for industrial use, macromolecules and biologically active substances, none of the foregoing for medical or veterinary use; kits for multiplex polymerase chain reaction (PCR) tests comprised of DNA primers for amplifying DNA and RNA loci | ACTIVE | — |
| 005 | Pharmaceutical medical preparations for treating infections; veterinary medical products, namely, vaccines; medical products for medical healthcare purposes, namely, reagents for medical use; diagnostic preparations for medical and veterinary purposes; diagnostic agents for medical and veterinary purposes, namely, diagnostic agents for medical and veterinary in-vitro diagnostics; diagnostic agents for medical and veterinary purposes, namely, biological diagnostic agents for testing diseases in cattle, pigs, and other animals; kits comprised of reagents for medical use, of antisense oligonucleotides being pharmaceutical preparations of monoclonal antibodies for use in disease testing, and of in-vitro diagnostic reagents and diagnostic control reagents all for medical purposes, sold as a unit for medical purposes; diagnostic test kits comprised of testing equipment in the nature of biomolecules, namely, antisense oligonucleotides being pharmaceutical preparations, primers in the nature of nucleic acid sequences and probes in the nature of single stranded sequences for DNA and RNA biomarker testing and DNA and RNA infectious disease testing for medical, veterinary, and dental purposes; products for medical and veterinary medical purposes, namely, diagnostic preparations for sample preparation, for modification and manipulation of cells and for labelling, for separation, for isolation, for purification, for amplification and for analysis of natural and synthetic biopolymers, in the nature of nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances all being diagnostic medical preparations; chemical, biochemical and biotechnological products, namely, reagents for medical use, for sample preparation, and for modification and manipulation of cells, all for medical use; in vitro diagnostic preparations for medical purposes; diagnostic disease testing kits comprised of medical diagnostic reagents; buffers for medical and veterinary purposes, namely, extraction buffers; diagnostic disease testing kits comprised of chemical reagents for medical use, antisense oligonucleotides being pharmaceutical preparations, nucleotides being pharmaceutical preparations, extraction buffers, in-vitro diagnostic preparations, and diagnostic control reagents, all for medical and veterinary use, sold as a unit for medical and veterinary use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by INDICAL BIOSCIENCE GmbH
- Other trademarks owned by INDICAL BIOSCIENCE GmbH
- Other trademarks owned by INDICAL BIOSCIENCE GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named INDIMIX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 1, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 11, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 11, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 14, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 14, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 14, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 17, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 17, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 28, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 5, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 5, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 5, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 18, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 28, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 28, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 9, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 9, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 9, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 6, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 6, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 6, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 26, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 6, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 6, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 9, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 8, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 1, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 27, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 23, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 22, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |